Select status:
Sort by:
Filter by last updated date

Please enter a valid month/year e.g. 01/2015

Pick a date between March 2000 and July 2021

Filter by area of interest
Filter by type
Showing 1 to 10 of 137
Title Reference number Published Last updated
Antimicrobial prescribing: nebulised liposomal amikacin Reference number:ES36 ES00036 Published:12 May 2021 20210512 Last updated:12 May 2021 20210512
Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis Reference number:ES35 ES00035 Published:24 February 2021 20210224 Last updated:24 February 2021 20210224
Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections Reference number:ES32 ES00032 Published:05 January 2021 20210105 Last updated:05 January 2021 20210105
Antimicrobial prescribing: cefiderocol Reference number:ES31 ES00031 Published:02 December 2020 20201202 Last updated:02 December 2020 20201202
Antimicrobial prescribing: imipenem with cilastatin and relebactam Reference number:ES30 ES00030 Published:28 October 2020 20201028 Last updated:28 October 2020 20201028
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis Reference number:ES29 ES00029 Published:21 July 2020 20200721 Last updated:21 July 2020 20200721
COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 Reference number:ES24 ES00024 Published:21 May 2020 20200521 Last updated:21 May 2020 20200521
COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Reference number:ES25 ES00025 Published:21 May 2020 20200521 Last updated:21 May 2020 20200521
COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis Reference number:ES26 ES00026 Published:21 May 2020 20200521 Last updated:21 May 2020 20200521
COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Reference number:ES23 ES00023 Published:14 April 2020 20200414 Last updated:14 April 2020 20200414